Enovis (NYSE:ENOV) Shares Down 6.4% – What’s Next?

Shares of Enovis Corporation (NYSE:ENOV) were down 6.4% during mid-day trading on Tuesday . The company traded as low as $22.87 and last traded at $23.0210. 184,825 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 1,071,094 shares. The stock had previously closed at $24.59.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ENOV shares. UBS Group reissued a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. BTIG Research upped their target price on Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, Wells Fargo & Company cut their target price on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.29.

Enovis Stock Performance

The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock has a 50-day moving average of $25.66 and a 200 day moving average of $24.28. The firm has a market capitalization of $1.27 billion, a P/E ratio of -1.15 and a beta of 1.34.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same quarter in the prior year, the company posted $0.79 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

Insider Transactions at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders bought 3,200 shares of company stock worth $69,864. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several large investors have recently made changes to their positions in the business. Arax Advisory Partners acquired a new stake in shares of Enovis in the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Allworth Financial LP acquired a new position in shares of Enovis in the 2nd quarter worth approximately $36,000. Danske Bank A S purchased a new stake in Enovis in the third quarter valued at $64,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Enovis during the second quarter worth about $48,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.